DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

H.C. Wainwright Reiterates Buy on Redhill Biopharma, Lowers Price Target to $14

H.C. Wainwright analyst Swayampakula Ramakanth reiterates Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $18 to $14.

Benzinga · 03/05/2020 12:50

H.C. Wainwright analyst Swayampakula Ramakanth reiterates Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $18 to $14.